The aim of the study was to compare antihypertensive efficacy and safety of ketanserin with those of enalapril in the treatment of hypertension. The study design was controlled, cross-over, with randomized sequences. The efficacy was evaluated from data of 19 (9 males, 10 females) mean age 59.5 +/- 10.1 years, weight kg 68 +/- 12.1 with hypertension lasting over 5 years. Posology was ketanserin 20-40 mg bid, and enalapril 10-20 mg bid; both for three weeks. The efficacy was good with both treatments and the effects similar. In fact, at the end of the treatment with ketanserin, supine SBP was decreased 10 +/- 20 and DBP 5 +/- 10 mmHg, standing SBP was reduced 15 +/- 19 and DBP 7 +/- 15 mmHg. With enalapril supine SBP decreased 25 +/- 16 and DBP 10 +/- 13 mmHg, standing SBP was reduced 16 +/- 19 and DBP 8 +/- 18 mmHg. Changes of heart rate by either treatment were of no clinical importance. The safety of treatment with ketanserin was excellent, while 14.3% of the patients treated with enalapril had undesirable effects.

[Cross-over study on the effects of ketanserin vs enalapril in the treatment of hypertension]

I Monte
Secondo
Data Curation
;
1995-01-01

Abstract

The aim of the study was to compare antihypertensive efficacy and safety of ketanserin with those of enalapril in the treatment of hypertension. The study design was controlled, cross-over, with randomized sequences. The efficacy was evaluated from data of 19 (9 males, 10 females) mean age 59.5 +/- 10.1 years, weight kg 68 +/- 12.1 with hypertension lasting over 5 years. Posology was ketanserin 20-40 mg bid, and enalapril 10-20 mg bid; both for three weeks. The efficacy was good with both treatments and the effects similar. In fact, at the end of the treatment with ketanserin, supine SBP was decreased 10 +/- 20 and DBP 5 +/- 10 mmHg, standing SBP was reduced 15 +/- 19 and DBP 7 +/- 15 mmHg. With enalapril supine SBP decreased 25 +/- 16 and DBP 10 +/- 13 mmHg, standing SBP was reduced 16 +/- 19 and DBP 8 +/- 18 mmHg. Changes of heart rate by either treatment were of no clinical importance. The safety of treatment with ketanserin was excellent, while 14.3% of the patients treated with enalapril had undesirable effects.
ketanserin; hypertension
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/545342
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact